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Abstract
Background: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant
disease burden amongst Māori and Pacific populations in New Zealand (NZ). However, contemporary data are
lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding
vaccine development.
Methods: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children
living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Māori or Pacific.
These children are among the highest risk group for developing ARF. Isolates were compared to concurrently
collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Māori and Pacific children and risk
of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine
candidate were undertaken as previously described.
Results: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were
detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from
children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D,
and more likely to be theoretically covered by the 30-valent M protein vaccine.
Conclusions: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from
children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types
and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same
country. This difference should be taken into account for vaccine development.
Background
Group A Streptococcus (GAS) is a major human patho-
gen, and infections caused by GAS are responsible for
considerable global morbidity and mortality [1]. The
spectrum of infections caused by GAS ranges from non-
invasive infections such as impetigo and pharyngitis,
through to invasive infections such as necrotizing
fasciitis and toxic shock syndrome. In addition, acute
rheumatic fever (ARF) and its sequela, rheumatic heart
disease (RHD) continue to represent a considerable dis-
ease burden in many settings. This includes New Zealand,
where the incidence of ARF in Māori and Pacific children
is amongst the highest in the developed world [2].
At present, molecular typing of GAS is performed by se-
quence analysis of the 5’ hypervariable region of the emm
gene that encodes the M-protein [3]. Recently, an emm
cluster-based typing system was proposed, which classifies
existing emm types into emm clusters based on genetic re-
latedness of emm protein sequences and functional activity
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of the M-protein [4]. This cluster system is predictive
of emm pattern type, which, based on differential
genotypic features and epidemiological associations, is
a proposed marker for GAS tissue tropism [4]. In
general, pattern A-C strains are associated with GAS
pharyngitis, pattern D strains with skin infections
(particularly impetigo), and pattern E strains with
both oropharyngeal and skin infections [5].
In response to rising rates of ARF in New Zealand, the
Rheumatic Fever Prevention Programme (RFPP) was set
up by the New Zealand Ministry of Health. The RFPP is
a multidisciplinary strategy aimed at reducing the inci-
dence of ARF by two-thirds, to 1.4 cases per 100,000
population by June 2017 [6]. A large part of this strategy
is focused on primary prevention of ARF, through the
timely diagnosis and treatment of GAS pharyngitis. One
of the models of care within this programme is the
provision of school-based sore throat management
clinics, with these services targeted at children at highest
risk of ARF [6]. In New Zealand the distribution of ARF
is unequal and those with the highest risk are Maori and
Pacific and live in areas of low socio economic areas in
the North Island [2]. The Counties Manukau region
(South Auckland, North Island) has the highest inci-
dence of rheumatic fever and the highest number of
school-based sore throat clinics.
Recent epidemiological analyses have demonstrated
that approximately half of ARF-associated GAS strains
in New Zealand fall into pattern D–i.e. strains classically
associated with skin infections [7]. Despite this associ-
ation, and the high incidence of skin infections in New
Zealand children [8], there have been few studies in New
Zealand describing the circulating GAS emm types asso-
ciated with superficial skin infections, and no contem-
porary studies comparing skin and pharyngeal isolates
from high-risk children. In addition, it is not known
whether there is any difference in GAS emm types circu-
lating amongst children at high risk of ARF, compared
to children with minimal risk.
The Coalition to Accelerate New Vaccines Against
Streptococcus (CANVAS) is an Australian and New
Zealand GAS vaccine development programme that aims
to identify suitable GAS vaccine candidates, with the long-
term aim of preventing GAS-related disease, particularly
ARF/RHD and invasive disease [9]. At present, the most
clinically advanced GAS vaccine candidates are those that
target the N-terminal region of the M-protein, such as an
experimental 30-valent M-protein vaccine [10, 11]. One of
the early aims of CANVAS is to define the global epidemi-
ology of circulating GAS strains, in order to better inform
vaccine development and putative vaccine coverage.
Accordingly, the aims of this study were to: (i) describe
the GAS emm types, emm clusters and patterns from
children at high risk of ARF with presumptive GAS
pharyngitis or skin disease in a New Zealand setting, (ii)
compare the emm types of GAS strains from children at
high risk of ARF with those at low risk, and (iii) deter-
mine the theoretical coverage of the 30-valent M-protein
vaccine candidate against contemporary GAS strains
associated with pharyngitis or skin disease.
Methods
Setting and population
Auckland is the largest city in New Zealand, with an es-
timated population of 1.47 million. The population is
ethnically diverse, consisting approximately of the fol-
lowing major ethnicities in 2013: 57 % European/Other,
21 % Asian, 12 % Pacific Peoples and 10 % Māori [12].
Labtests Auckland (LTA) is the sole community diagnos-
tic microbiology provider for the entire Auckland region.
This includes testing for GAS from: (i) primary care, and
(ii) school-based sore throat management programs that
are part of the RFPP in Auckland. Between 1st April and
25th June 2015, GAS isolates were collected from throat
swabs taken from children aged 5 to 15 years presenting
with presumptive pharyngitis in school-based programs,
as part of the previously described RFPP [6]. Children
enrolled in the sore throat management programmes are
at highest risk of developing ARF so tend to be of Māori
or Pacific ethnicity and living in areas of high social
deprivation. During the same time period, GAS skin iso-
lates were collected from children aged 5 to 15 years
who presented to a general practitioner with a presump-
tive skin infection. These samples were collected from
primary care practitioners from the same geographic
region (i.e. areas of high social deprivation) as the throat
swabs.
In order to provide a comparator population, GAS
isolates were collected between 1st April and 30th
May 2015 from throat swabs taken from children
aged 5 to 15 years in Dunedin, a city in the South
Island of New Zealand. These GAS isolates were col-
lected from children presenting to a general practi-
tioner with presumptive pharyngitis. The population
in Dunedin is predominantly European (84 %),
followed by Māori (7 %), Asian (6 %) and Pacific
Peoples (2 %) [12]. The incidence of ARF in children
in Dunedin is negligible, with only one case of ARF
reported in the last five years.
Basic demographic data were collected about each
child who had GAS isolated, including age, sex, ethnicity
and socioeconomic status, as determined by the New
Zealand deprivation index (NZDep). The NZDep score
is an area-based measure of socioeconomic deprivation
derived from New Zealand census data, which assigns a
decile ranking from 1 to 10, with 10 representing the
most deprived neighbourhoods [13].
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Bacterial isolates and molecular typing
Throat and skin swabs were plated onto tryptic soy
sheep blood agar and incubated in 5 % CO2 overnight at
37 °C. GAS isolates were identified using a MALDI-TOF
MS Biotyper (Bruker, Germany) and forwarded to the
Invasive Pathogens Laboratory at the Institute of Environ-
mental Science and Research, Wellington, New Zealand
for further analysis. Polymerase chain reaction (PCR) and
DNA sequencing of the emm gene was performed using
previously described methods [3]. Emm clusters, along
with emm patterns, were extrapolated from emm typing
results [4].
Statistical analysis
Simpson’s index of diversity was used to assess variation
in emm types. This index indicates the probability that
two emm types randomly selected are of different types–
i.e. the higher the index, the greater the diversity of emm
types in a particular population [14]. 95 % confidence in-
tervals (CI) for the Simpson’s index were calculated as
previously described [15]. Statistical analysis was per-
formed using GraphPad Prism (Version 6), and a p value
of 0.05 was considered significant.
Ethical approval
As this study involved de-identified patient data, ethical
approval was not deemed necessary by the Health and
Disability Ethics Committees, New Zealand.
Results
Population demographics
A total of 452 isolates (246 pharyngeal isolates from
Auckland, 104 skin isolates from Auckland and 103
pharyngeal isolates from Dunedin) were collected from
452 children. In Auckland, over 80 % of children in both
groups (i.e. those with either a pharyngeal or skin iso-
late) were either Māori or Pacific, and predominantly
resided in areas of high socioeconomic deprivation pla-
cing them in the high-risk group for developing ARF
(Table 1). In contrast, over 80 % of children with a
pharyngeal isolate in Dunedin were European, and re-
sided in areas of low and moderate socioeconomic
deprivation placing them in the low-risk group for devel-
oping ARF (Table 1).
emm typing and cluster analysis
Amongst the 452 isolates, a total of 83 emm types were
detected, belonging to 20 emm clusters (Additional file
1: Table S1). Amongst Auckland isolates, the Simpson’s
index did not differ significantly (on the basis of non-
overlapping confidence intervals) between pharyngeal
isolates (96.3 % [95 % CI 95.5 to 97.1 %]) and skin iso-
lates (96.3 % [95 % CI 95.3 to 97.3 %]). However, the
Simpson’s index was significantly lower in pharyngeal
isolates from Dunedin (87.5 % [95 % CI 86.1 to 88.9 %]).
There were notable differences in emm cluster distri-
bution according to specimen site and geographical loca-
tion, with cluster D4 more common amongst skin
isolates (36 % in Auckland skin isolates vs. 15 % in
Auckland pharyngeal isolates vs. 3 % in Dunedin
pharyngeal isolates), and clusters A-C4 and E4 more
common amongst pharyngeal isolates, particularly from
Dunedin (Table 2). Strains belonging to pattern D (skin
pattern) made up 52 % of isolates recovered from skin,
32 % of pharyngeal isolates in Auckland, 4 % of
pharyngeal isolates from Dunedin and 44 % of ARF
associated strains reported in a previous study in
New Zealand [7] (Fig. 1).
Theoretical M-protein vaccine coverage
The theoretical coverage of the experimental 30-valent M-
protein vaccine was lower for skin-associated isolates than
for pharyngeal isolates (Table 3). Amongst Auckland
isolates, theoretical coverage increased significantly in
Table 1 Demographic characteristics of children with group A Streptococcal pharyngeal and skin isolates
Characteristic Pharyngeal isolates, Auckland
(n = 246) (%)
Skin isolates, Auckland
(n = 104) (%)
Pharyngeal isolates, Dunedin
(n = 103) (%)
Age, median, years [IQR] 8.4 [6.4–11.1] 7.4 [6.1–10.0] 8.2 [7.2–9.2]
Male sex 125 (51) 52 (50) 51 (51)
Ethnicity
European / Other 27 (11) 11 (11) 85 (82)
Māori 68 (28) 41 (39) 13 (13)
Pacific 147 (60) 47 (45) 0
Asian 4 (1) 5 (5) 5 (5)
NZDep
Low 3 (1) 6 (6) 33 (32)
Medium 14 (6) 25 (24) 44 (43)
High 229 (93) 73 (70) 26 (25)
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both groups when the potential effect of cross-opsonic
antibodies was considered, although still only covered
approximately half of skin isolates. There was a significant
difference in theoretical vaccine coverage between
pharyngeal isolates from Auckland and those from
Dunedin, with coverage almost twice as high amongst GAS
isolates from Dunedin compared to Auckland (Table 3).
Discussion
This study describes the contemporary molecular epi-
demiology of GAS strains circulating amongst high-risk
children in a setting with a high burden of ARF, com-
pared with strains amongst children residing in the same
country, with minimal risk of ARF [2]. As expected,
emm pattern D, classically associated with skin tropism,
predominated in GAS skin isolates in high-risk children
accounting for approximately half of all emm types.
Somewhat surprisingly, approximately one-third of
strains from high-risk children in Auckland with pre-
sumptive GAS pharyngitis also belonged to emm pattern
D. This is in marked contrast to the distribution
observed in pharyngeal isolates from low-risk children in
Table 2 emm clusters of group A Streptococcal strains isolated from children in New Zealand, 2015
Cluster Pharyngeal isolates, Auckland
(n = 246) (%)
Skin isolates, Auckland
(n = 104) (%)
Pharyngeal isolates, Dunedin
(n = 103) (%)
P a
A-C2 - 1 (1) - NS
A-C3 24 (10) 4 (4) 7 (7) NS
A-C4 30 (12) 1 (1) 21 (21) <0.01
A-C5 1 (<1) - 1 (<1) NS
D1 6 (2) - - NS
D2 9 (4) 5 (5) - NS
D3 1 (<1) - - NS
D4 38 (15) 37 (36) 3 (3) <0.01
E1 4 (10) 1 (1) 6 (6) NS
E2 13 (5) 9 (9) 3 (3) NS
E3 56 (23) 18 (17) 4 (4) <0.01
E4 24 (10) 6 (6) 51 (50) <0.01
E5 1 (<1) - - NS
E6 27 (11) 19 (18) 7 (7) 0.018
M105 2 (<1) - - NS
M111 3 (1) - - NS
M19 1 (<1) 2 (2) - NS
M218 2 (<1) - - NS
M233 1 (<1) - - NS
M74 3 (1) 1 (1) - NS
a Significance values determined by 3 × 2 χ2 test
NB–emm clusters are based on those proposed by Sanderson-Smith et al. [4]
Fig. 1 emm patterns of group A streptococcal strains associated with pharyngitis, skin infections and rheumatic fever in New Zealand. The
rheumatic fever isolates (*) were published previously [7]
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Dunedin, where pattern D strains comprised only 4 % of
isolates. Though emm pattern type has been described
as an imperfect marker for tissue tropism [5], the high
prevalence of emm pattern D strains observed in high-
risk children in this study resembles observations in
Aboriginal children in Australia, another Indigenous
population with high ARF risk. A study in three remote
Aboriginal communities found emm pattern D strains
accounted for 53 % of pyoderma isolates and 24 % of
pharyngeal isolates [16].
Clear differences were also observed in emm cluster
types between high-risk and low risk children in this
study. The emm clusters observed in pharyngeal iso-
lates from low-risk Dunedin children closely resemble
findings from other developed countries. [17]. For ex-
ample, Shulman et al., recently applied the emm clus-
ter system to pharyngitis isolates collected between
2000–2007 in the United States and found that clus-
ters E4, A-C3 and A-C4 comprised 62.5 % of
pharyngeal isolates, with isolates from cluster D4
representing <1 % of isolates [17]. In our study, clus-
ters E4, A-C3 and A-C4 comprised 79 % of
pharyngeal isolates from Dunedin, but only 45 % of
pharyngeal isolates from Auckland. Isolates from clus-
ter D4 accounted for just 3 % of pharyngeal strains in
low-risk Dunedin children in our study but 15 % of
pharyngeal strains in high-risk Auckland children and
were the most prevalent cluster amongst GAS skin
isolates comprising 36 % of strains. The emm-cluster
D4 comprises 32 emm-types [4], and was also the
most prevalent cluster in a recent analysis of GAS
isolates collected in Fiji where it accounted for over
30 % of strains [18].
The high proportion of emm pattern D and cluster D4
amongst GAS skin and pharyngeal isolates in Auckland
(an area with the highest rates of ARF in New Zealand)
is in keeping with recent work describing a high propor-
tion of emm pattern D and cluster D4 isolates amongst
ARF-associated GAS strains in New Zealand [7]. Taken
together these observations add further weight to the hy-
pothesis that skin infections may play an important etio-
logical role in the pathogenesis of ARF [7, 19]. Although
the biological pathway is unclear, it is possible that
colonizing GAS skin isolates may passage into the phar-
ynx, or alternatively antecedent skin infection may
‘prime’ the immune system in an, as yet, uncharacterized
manner, and contribute to the autoimmune process
characteristic of ARF [20].
Previous studies have shown the theoretical cover-
age of the 30-valent GAS vaccine is reduced in low-
income countries where the diversity of emm-types is
highest [21]. In this study, vaccine coverage has been
compared between different populations within the
same country. The theoretical coverage was low
amongst isolates from high-risk Auckland children for
which the Simpson’s index for strain diversity is high,
although did increase when the putative effect of
cross-opsonic antibodies was considered. However ap-
proximately 40 % of skin-associated isolates and 28 %
of Auckland pharyngeal isolates have not yet been
tested for potential cross-opsonic activity [10, 11]. In
contrast, the theoretical vaccine coverage for
pharyngeal isolates from low-risk children in Dunedin
is 93.2 % before taking into account the added poten-
tial effect of in vitro cross-opsonization. The high
theoretical coverage in this low-risk population likely
reflects the similarities in emm-clusters observed with
pharyngeal strains from the US [17], as the 30-valent
vaccine was designed to include emm-types commonly
associated with pharyngitis in North America [10].
These findings demonstrate the importance of broad
population sampling when assessing theoretical vac-
cine coverage.
There were a number of limitations with this study. It
was assumed that GAS pharyngeal isolates were from
children with pharyngitis, although information on clin-
ical symptoms was not available for each child. Within
the school-based programme, children are encouraged
to present for assessment when they have a sore throat,
though it remains possible that some of these isolates
represent GAS colonization with concurrent viral pha-
ryngitis, rather than true, serologically confirmed, GAS
pharyngitis [22]. Similarly, clinical information about
each child who had a skin swab submitted for testing
was not available. However, as these swabs were submit-
ted as part of a primary care consultation, it is likely that
Table 3 Theoretical coverage of 30-valent vaccine in relation to Group A Streptococcus-associated clinical syndromes
Pharyngeal GAS isolates,
Auckland; n = 246
(95 % CI)
Skin GAS isolates,
Auckland; n = 104
(95 % CI)
Pharyngeal GAS isolates,
Dunedin; n = 103
(95 % CI)
Theoretical 30-valent coverage 48.4 % (42.2 %–54.6 %) 33.7 % (25.3 %–43.2 %) 93.2 % (86.4 %–96.9 %)
Theoretical additional coverage with
cross-opsonic effect a
69.5 % (63.4 %–74.9 %) 54.8 % (45.2 %–64.0 %) 95.1 % (88.9 %–98.2)
Proportion of isolates belonging to emm
types not tested for cross-opsonic effect a
27.6 % (22.4 %–33.6 %) 38.5 % (29.7 %–48.1 %) 2.9 % (0.6 %–8.6 %)
a As determined from references [8, 9] in which a percentage killing of 50 % or greater is considered significant in bactericidal assays
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the majority of children had clinical symptoms suggest-
ive of a skin infection. Moreover, our sampling period
was over a relatively short timeframe; previous work, in-
cluding a study from New Zealand, has demonstrated
temporal variation in the proportional distribution of
GAS emm types.
Conclusions
In summary, this study describes a high diversity of
emm types and a high proportion of emm-pattern D
and cluster D4 isolates amongst children at high risk
of ARF in New Zealand. These findings have potential
impact on the theoretical coverage of multivalent M-
protein vaccines in high-risk populations in New
Zealand. In contrast, pharyngeal isolates from children
at low risk of ARF within the same country were less
diverse, less likely to be emm pattern D, and more
likely to be theoretically covered by the 30-valent M
protein vaccine. The high proportion of emm pattern
D GAS strains amongst skin and pharyngeal isolates
from children at high risk of ARF further highlights
the potential role of skin infections in the pathogenesis of
ARF.
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